Fierce Pharma

JUNE 28, 2023

With a spring approval in hand, Reata Pharmaceuticals has been waiting patiently to launch its first commercial product, Skyclarys. After an FDA thumbs up on Reata's approval supplement for Skyclarys, analysts feel confident the newly commercial-stage company can meet—or potentially even exceed—a $45.9

FDA 215

FDA Sales Pharmaceutical Patients 215

Rep-Lite

APRIL 4, 2024

Sales representatives play a crucial role in connecting healthcare facilities with innovative technologies that improve patient care. Here are some key tips for success in medical device sales: 1. This demonstrates your commitment to patient care and positions you as a valuable resource beyond simply selling a product.

Medical 52

Medical Sales Interpersonal Skills Ethics 52

pharmaphorum

JULY 15, 2022

Pfizer’s tyrosine kinase inhibitor Xalkori has picked up a fourth approval from the FDA, adding a new use in the treatment of a rare form of benign tumour that typically affects children and young adults. The post FDA clears Xalkori for inflammatory myofibroblastic tumours appeared first on.

FDA 114

FDA Sales Patients Marketing 114

pharmaphorum

JANUARY 27, 2023

AstraZeneca’s revenue boost from COVID-19 therapy Evusheld looks set to be curbed early, as the FDA withdraws authorisation for the antibody on the grounds that it is ineffective against most subvariants now circulating in the US. and other XBB subvariants, said the FDA in an update. Evusheld is also ineffective against the BQ.1,

FDA 127

FDA Sales Marketing Medical 127

European Pharmaceutical Review

NOVEMBER 2, 2023

The US Food and Drug Administration ( FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). He added that the approval of Wezlana “could have a meaningful impact for patients managing their disease.” US sales of Stelara totalled $6.4

Food and Drug Administration 90

Food and Drug Administration FDA Side effects Safety 90

Rep-Lite

NOVEMBER 30, 2023

B2B sales consulting for medical sales is a specialized service that helps healthcare organizations navigate the unique challenges of B2B transactions within the healthcare industry. What is B2B Sales Consulting? A sales expert in this space needs to understand these intricacies and provide tailored solutions.

B2B Sales 52

B2B Sales Medical sales Consulting Sales 52

Legacy MEDSearch

SEPTEMBER 12, 2023

Food and Drug Administration (FDA) has approved the LimFlow System to help people with CLTI who have no other suitable endovascular or surgical treatment options and are facing major amputation. 4 The LimFlow System is the first and only FDA-approved device for TADV and previously received Breakthrough Device Designation from the FDA. “At

FDA 52

FDA Patients Food and Drug Administration Recruitment 52

Legacy MEDSearch

OCTOBER 4, 2023

Stimdia Medical, a medical device company developing innovative technologies to improve respiratory care, today announced the initiation of its FDA approved pivotal trial to investigate the impact of phrenic nerve stimulation (PNS) on the time to liberate patients from mechanical ventilation.

Medical 52

Medical Patients FDA Recruitment 52

Contrarian Sales Techniques

DECEMBER 5, 2023

Did you know that a well-trained pharmaceutical sales rep can be the driving force behind a healthcare provider's decision-making process? Welcome to the world where sales training isn't just a formality. In this post, we’re diving deep into the realm of pharmaceutical sales training. That’s right.

Pharmaceutical Sales 52

Pharmaceutical Sales Training Sales Pharmaceutical 52

Rep-Lite

MARCH 14, 2024

Medical sales representatives are the medium through which medical companies sell their healthcare products to providers like hospitals and clinics. Medical sales rep requirements include technical knowledge of medical equipment and technologies, sales skills, and interpersonal abilities. Why Pursue a Career in Medical Sales?

Medical sales reps 52

Medical sales reps Medical sales Medical Sales 52

pharmaphorum

JULY 19, 2022

The FDA’s decision to clear the new indication for the topical JAK1/JAK2 inhibitor came after a priority review that was delayed by a request for additional data by the regulator, holding back a decision by three months. The company is gunning for sales in atopic dermatitis alone of $1.5

FDA 91

FDA Side effects Sales Safety 91

Legacy MEDSearch

SEPTEMBER 12, 2022

Food and Drug Administration (FDA) 510(k) clearance and launch of a next-generation RhinAer® stylus. The new RhinAer is designed to provide physicians with improved visualization, easier access and tissue apposition, especially in patients with narrow nasal airways. Aerin Medical Inc.,

Medical 98

Medical FDA Patients Physicians 98

Legacy MEDSearch

SEPTEMBER 18, 2023

Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) supplement to permit the expansion of the study of the eShunt System in patients with Normal Pressure Hydrocephalus (NPH) to additional study participants and clinical sites. CereVasc, Inc., Carl Heilman, M.D., and Adel Malek, M.D.,

Food and Drug Administration 52

Food and Drug Administration FDA Patients Recruitment 52

Pharmaceutical Technology

MARCH 30, 2023

Biogen/Eisai’s newly approved drug, Leqembi (lecanemab), gained FDA approval in January 2023 for the treatment of Alzheimer’s disease. The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is currently pending approval in the EU and Japan.

Sales 59

Sales FDA Marketing Competition 59

Legacy MEDSearch

DECEMBER 12, 2022

This most recent FDA 510(k) clearance extends the system’s previous FDA clearances and permits the activation of software functionality that connects to the patient’s bedside monitor and openly transmits treatment information to the central nursing station. ” About IRRAS. Press Release by: IRRAS.

FDA 95

FDA Food and Drug Administration Recruitment Networking 95

pharmaphorum

DECEMBER 30, 2022

The FDA’s interactions with Biogen in the build-up to last year’s controversial approval of Alzheimer’s disease therapy Aduhelm have been described as “inappropriate” and “atypical” in a congressional report on the review.

FDA 59

FDA Sales Marketing Patients 59

Legacy MEDSearch

MARCH 1, 2024

Food and Drug Administration (FDA) for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease. physicians the opportunity to treat their patients with this novel device.” of balloon angioplasty patients and 17.9% of AGENT DCB patients. Are you hiring?

Food and Drug Administration 52

Food and Drug Administration FDA Recruitment Physicians 52

Pharmaceutical Technology

MARCH 30, 2023

Biogen/Eisai’s newly approved drug, Leqembi (lecanemab), gained FDA approval in January 2023 for the treatment of Alzheimer’s disease. The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is currently pending approval in the EU and Japan.

Sales 52

Sales FDA Marketing Competition 52

Legacy MEDSearch

JUNE 9, 2023

Food and Drug Administration (FDA) has granted approval for the DETOUR System to treat patients with complex peripheral arterial disease (PAD). At present, patients with long blockages of the superficial femoral artery (SFA) have limited treatment options. million Americans are affected by PAD.

FDA 52

FDA Patients Food and Drug Administration Recruitment 52

Legacy MEDSearch

APRIL 6, 2023

announced that it has received FDA 510(k) clearance for CardioSTAT, an ambulatory, continuous ECG monitoring solution that relies on a wire free, single-use recorder. The FDA clearance opens the door to the world’s largest medical device market. To this day, CardioSTAT has been prescribed to more than 170,000 patients.

Food and Drug Administration 98

Food and Drug Administration Food FDA Recruitment 98

Pharmaceutical Technology

APRIL 12, 2023

Pharming Group has conducted the first commercial shipments of oral selective PI3Kδ inhibitor Joenja (leniolisib) to patients diagnosed with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in the US. Under its terms, Pharming has paid a $10m milestone payment to Novartis for the first commercial sale of Joenja.

Food and Drug Administration 59

Food and Drug Administration Patients FDA Food 59

Legacy MEDSearch

OCTOBER 24, 2023

Food and Drug Administration (FDA) for its novel coronary artery bifurcation stenting technology. “The FDA’s Breakthrough Device Designation is a testament to the potential of our technology to address a critical unmet need in interventional cardiology,” said Dr. . Are you hiring?

FDA 52

FDA Food and Drug Administration Recruitment Food 52

Legacy MEDSearch

SEPTEMBER 13, 2022

Potrero Medical announced that the FDA granted Breakthrough Device Designation for their AKI Predict machine learning algorithm, for the advanced prediction of acute kidney injury (AKI) associated with intra-abdominal hypertension (IAH) in cardiac post-surgical intensive care patients. About Potrero Medical. Potrero Medical, Inc.

Medical 98

Medical FDA Recruitment Management 98

Contrarian Sales Techniques

JANUARY 25, 2023

When I first started working as a pharmaceutical sales representative, I didn't fully understand the importance of compliance with regulatory requirements. Regulatory requirements such as HIPAA and FDA regulations are put in place to protect patient's safety and ensure that all sales and marketing efforts are compliant.

Pharmaceutical Sales 52

Pharmaceutical Sales Sales Pharmaceutical Safety 52

MedReps

JANUARY 30, 2023

Knowing what’s to come in the medical sales industry is not only interesting, but it could help you with your sales goals. Medical Sales Trends to Watch Out For in 2023 If you want to know what the future holds and create some forward-thinking sales goals, then check out these medical sales trends to watch out for in 2023.

Medical sales 74

Medical sales Medical Sales Sales goal 74

Evolve Your Success

OCTOBER 3, 2023

Diagnostic testing sales: where meticulous detail meets the human touch, changing the course of cancer care one relationship at a time. In this special episode for Breast Cancer Awareness Month, Veronica Vasek uncovers the challenges, triumphs, and the vital role that diagnostic sales reps play in the healthcare landscape.

Sales 64

Sales Medical sales Physicians Medical 64

Legacy MEDSearch

SEPTEMBER 27, 2022

Food and Drug Administration (FDA) 510(k) clearance for its CellFX System, expanding the indication for use to include the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-III. See Full Press Release at the Source: Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia.

FDA 98

FDA Food and Drug Administration Recruitment Medicine 98

Pharmaceutical Technology

APRIL 28, 2023

Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a sales growth of 23% in 2023. Ozempic’s forecast 2023 sales of $12.5bn consolidate its position as the dominant market leader, with projected sales in 2023 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly, which anticipates sales of $8bn.

Sales 52

Sales Marketing Medical Patients 52

Legacy MEDSearch

OCTOBER 10, 2023

Hammerdesis allows surgeons to correct hammertoe deformities and degenerative issues in patients by simply affixing a distinctively designed implant on the patient’s toe joint. Dr. David Murphy, DPM FACFAS remarked, “ Hammerdesis provides patients with a more reliable, and a more consistent option to fix hammertoe issues.

Food and Drug Administration 52

Food and Drug Administration FDA Recruitment Marketing 52

Pharmaceutical Technology

MAY 25, 2023

Celltrion USA has received approval from the US Food and Drug Administration (FDA) for Humira (adalimumab) biosimilar, Yuflyma (adalimumab-aaty) , for multiple indications. It will be offered to patients in prefilled syringe and autoinjector administration options. The company intends to launch the biosimilar in the US in July 2023.

Food and Drug Administration 52

Food and Drug Administration FDA Food Safety 52

Legacy MEDSearch

NOVEMBER 1, 2022

Food & Drug Administration (FDA) for its smaller-diameter CurvaFix® IM Implant indicated for fixation of fractures of the pelvis. The new 7.5mm device is designed to simplify surgery and to provide strong, stable, curved fixation in smaller patients. CurvaFix, Inc., every year. About CurvaFix, Inc. CurvaFix, Inc.

Food and Drug Administration 98

Food and Drug Administration FDA Recruitment Food 98

pharmaphorum

AUGUST 16, 2022

AstraZeneca and Merck & Co’s PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see its use broadened if a new marketing application is approved by the FDA. The post FDA grants swift review to Lynparza in first-line prostate cancer appeared first on.

FDA 94

FDA Patients Sales Marketing 94

Legacy MEDSearch

APRIL 7, 2023

Food and Drug Administration (FDA) has granted 510(k) clearance to the Axiom PSR System for use with the company’s Kinos Axiom Total Ankle System. The Axiom PSR metal resection guides sit noticeably better on the bone and offer greater saw control compared to the historically polymer patient-specific instruments.

FDA 52

FDA Patients Food and Drug Administration Recruitment 52

pharmaphorum

JULY 25, 2022

AstraZeneca and Daiichi Sankyo will hear back from the FDA before the end of 2022 on their license application for Enhertu in HER2-low breast cancer – an indication which could drive the drug into multibillion-dollar sales territory. The post FDA verdict on Enhertu in HER2-low breast cancer due before year-end appeared first on.

FDA 59

FDA Sales territory Sales Patients 59

Evolve Your Success

OCTOBER 24, 2023

OEM Sales is about creating solutions to win customers and making an impact, one deal at a time. In this episode, we have Sean Pitts from GCX corporation to uncover the ins and outs of OEM Sales. Sean discusses the critical qualities that make an exceptional OEM sales representative. If y ou ask, “W hat is OEM sales ?”

Sales 64

Sales Medical Manufacturing Medical sales 64

Legacy MEDSearch

SEPTEMBER 16, 2022

Food and Drug Administration (FDA) has cleared its Tasso+ lancet as a Class II medical device. Healthcare systems and physicians will also be able to use the Tasso+ device with compatible collection tubes to make determinations on blood chemistries for their patients and expand care access. Tasso, Inc., About Tasso.

Medical 97

Medical FDA Food and Drug Administration Recruitment 97

Legacy MEDSearch

NOVEMBER 28, 2022

Director of Global Sales and Marketing of NeuroLogica. The BodyTom 64 brings the power of innovative imaging to patients’ bedsides safely and efficiently. See Full Press Release at the Source: NeuroLogica Announces FDA 510(k) Clearance of BodyTom® 64. For more information, please visit: www.NeuroLogica.com. Are you hiring?

FDA 92

FDA Food and Drug Administration Electronics Recruitment 92